Dr. Bhuyan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3900 Woodland Ave
University And Woodland Avenues
Philadelphia, PA 19104
Education & Training
- University of Pennsylvania Health SystemFellowship, Infectious Disease, 2001 - 2003
- Emory University School of MedicineResidency, Internal Medicine, 1998 - 2001
- University of Texas Southwestern Medical SchoolClass of 1998
Certifications & Licensure
- PA State Medical License 2001 - 2024
- GA State Medical License 1999 - 2001
Clinical Trials
- Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) Start of enrollment: 2006 May 01
- Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED) Start of enrollment: 2006 Sep 01
- A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) Start of enrollment: 2006 Oct 06
- Join now to see all
Publications & Presentations
PubMed
- 41 citationsVery rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis.Prakash Bhuyan, Jennie Medin, Hugo Gomes da Silva, Madhavi Yadavalli, Nirmal Kumar Shankar
Lancet. 2021-08-14 - 19 citationsSafety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 yearsChristopher L. Gilbert, Stephanie O. Klopfer, Jason C. Martin, Florian Schödel, Prakash K. Bhuyan
Human Vaccines. 2011-12-01 - 6 citationsSafety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.Gianmaria Minervini, Barbara J. McCarson, Keith S. Reisinger, Jason C. Martin, Jon E. Stek
Vaccine. 2012-02-14
Press Mentions
- INOVIO to Present at Upcoming Investor Conferences in MarchMarch 2nd, 2021
- Inovio Pharmaceuticals Inc (NASDAQ: INO) Q1 2020 Earnings Call TranscriptMay 11th, 2020
- INOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-Associated Vulvar DysplasiaMarch 30th, 2020
- Join now to see all
External Links
- LinkedIN https://www.linkedin.com/in/prakash-bhuyan-a4584310/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: